Ovulation pain is common and affects about 40% of people who ovulate. You may have mild ovulation pain, but see a doctor if it is severe or comes with other symptoms. Over-the-counter (OTC) pain ...

Adding tucatinib to standard first-line maintenance therapy in patients with HER2-positive metastatic breast cancer led to a clinically meaningful delay in disease progression, regardless of the ...

Obesity accelerates the rise of Alzheimer’s-related blood biomarkers far more rapidly than previously recognized. Long-term imaging and plasma data show that obese individuals experience much faster ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. The current standard of care for the ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA ® (tucatinib) as part of an ...

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...

Guardant Health is touting the results of a new study showing its Reveal blood test can detect whether chemotherapy is failing months before evidence shows up on regular scans, allowing oncologists to ...

Ovulation fatigue and exhaustion can occur during and after ovulation. It’s associated with fluctuations in hormones, including estrogen and progesterone. If you feel tired or exhausted in the weeks ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a commercial-stage precision care company pioneering biomarker-driven solutions for multiple sclerosis (MS) and other neurodegenerative ...

As construction of the new Purple Line light rail makes steady progress toward its estimated opening in two years, News4 took an exclusive test ride. “This is really exciting to be on the light rail ...